Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

completed350%
terminated233%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Fotemustine in Treating Patients With Metastatic Melanoma

NCT00560118
completedphase_3

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

NCT01359956
completedphase_2

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

NCT01069627
completedphase_2

A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma

NCT01474239
unknownphase_3

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

NCT02460068
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00560118Phase 2

Fotemustine in Treating Patients With Metastatic Melanoma

Terminated
NCT01359956Phase 3

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Completed
NCT01069627Phase 2

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Completed
NCT01474239Phase 2

A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma

Completed
NCT02460068Phase 3

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

Unknown
NCT00110123Phase 3

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6